Viatris reports strong fourth quarter and full year 2022 financial results and provides 2023 financial guidance

Pittsburgh , feb. 27, 2023 /prnewswire/ --  company meets its 2022 adjusted guidance after incorporating the fourth quarter impact of the biosimilars transaction and acquired ipr&d 2023 guidance midpoint reflects revenue growth over 2022, excluding full-year impact of biosimilars reaffirms 2024 phase 2 outlook from november 7 strategic update company increases return of capital to shareholders by completing $250 million in share repurchases board of directors approves 2023 dividend policy of forty-eight cents ($0.48) per share and declares first quarter dividend of twelve cents ($0.12) per share paid down debt of approximately $3.3 billion in 2022, retiring $5.4 billion of debt since 2021 remains on track to execute planned divestitures viatris inc. (nasdaq: vtrs) today reported strong results for the fourth quarter and full year 2022, meeting its adjusted guidance range for 2022 after incorporating the fourth quarter impact of the closing of the transaction pursuant to which the company contributed its biosimilars portfolio to biocon biologics (the "biosimilars transaction") and acquired ipr&d. financial impact of completion of the biosimilars transaction and acquired ipr&d the 2022 financial guidance metrics were impacted by the biosimilars transaction and acquired ipr&d as follows: (in millions) 2022 guidanceranges(1) (november 7, 2022) biosimilars transaction acquired ipr&d adjusted 2022 guidance ranges(1) 2022 results total revenues $16,200 - $16,700 $(86) $— $16,100 - $16,600 $16,263 adjusted ebitda $5,800 - $6,200 $(31) $(36) $5,725 - $6,125 $5,777(2) free cash flow $2,500 - $2,900 $(274) $(36) $2,200 - $2,600 $2,547(2) ___________ (1) viatris did not provide forward-looking guidance for comparable u.s. gaap net earnings (loss) or a quantitative reconciliation of its 2022adjusted ebitda guidance.
VTRS Ratings Summary
VTRS Quant Ranking